Latest & greatest articles for rivaroxaban

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on rivaroxaban or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on rivaroxaban and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for rivaroxaban

81. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal

Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal Stevenson M, Scope A, Holmes M, Rees A, Kaltenthaler E Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation Stevenson M, Scope A, Holmes M, Rees A, Kaltenthaler E. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal. Health Technology Assessment 2009; 13(Suppl 3 Article 7): 43-48 Final publication URL PubMedID Additional data URL Indexing Status Subject indexing assigned by NLM MeSH Adult; Anticoagulants /economics /therapeutic use; Arthroplasty, Replacement, Hip /adverse effects; Arthroplasty, Replacement, Knee /adverse effects; Cost-Benefit

Health Technology Assessment (HTA) Database.2009

82. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the Irish healthcare setting

A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the Irish healthcare setting A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the Irish healthcare setting A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium (...) as thromboprophylaxis after total hip and total knee replacement in the Irish healthcare setting McCullagh L, Tilson L, Walsh C, Barry M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of rivaroxaban

NHS Economic Evaluation Database.2009

83. Dabigatran or Rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative clinical-effectiveness and safety

Dabigatran or Rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative clinical-effectiveness and safety Dabigatran or Rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative clinical-effectiveness and safety Dabigatran or Rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative (...) clinical-effectiveness and safety Ndegwa S, Moulton K, Argaez C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Ndegwa S, Moulton K, Argaez C. Dabigatran or Rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative clinical-effectiveness and safety . Ottawa: Canadian Agency

Health Technology Assessment (HTA) Database.2009

84. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.

Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. 19539361 2009 07 06 2009 07 17 2016 07 20 1474-547X 374 9683 2009 Jul 04 Lancet (London, England) Lancet Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. 29-38 10.1016/S0140-6736(09)60738-8 Rivaroxaban is an oral direct factor Xa inhibitor that has been effective in prevention (...) of venous thromboembolism in patients undergoing elective orthopaedic surgery. However, its use after acute coronary syndromes has not been investigated. In this setting, we assessed the safety and efficacy of rivaroxaban and aimed to select the most favourable dose and dosing regimen. In this double-blind, dose-escalation, phase II study, undertaken at 297 sites in 27 countries, 3491 patients stabilised after an acute coronary syndrome were stratified on the basis of investigator decision to use

Lancet2009

85. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. 19411100 2009 05 18 2009 06 01 2016 11 25 1474-547X 373 9676 2009 May 16 Lancet (London, England) Lancet Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. 1673-80 10.1016/S0140-6736(09)60734-0 Prophylaxis for venous thromboembolism is recommended for at least 10 days after total knee arthroplasty; oral regimens could (...) enable shorter hospital stays. We aimed to test the efficacy and safety of oral rivaroxaban for the prevention of venous thromboembolism after total knee arthroplasty. In a randomised, double-blind, phase III study, 3148 patients undergoing knee arthroplasty received either oral rivaroxaban 10 mg once daily, beginning 6-8 h after surgery, or subcutaneous enoxaparin 30 mg every 12 h, starting 12-24 h after surgery. Patients had mandatory bilateral venography between days 11 and 15. The primary

Lancet2009

87. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.

Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. 18579811 2008 06 26 2008 07 01 2015 11 19 1533-4406 358 26 2008 Jun 26 The New England journal of medicine N. Engl. J. Med. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. 2765-75 10.1056/NEJMoa0800374 This phase 3 trial compared the efficacy and safety of rivaroxaban, an oral direct inhibitor of factor Xa, with those of enoxaparin for extended thromboprophylaxis in patients undergoing (...) total hip arthroplasty. In this randomized, double-blind study, we assigned 4541 patients to receive either 10 mg of oral rivaroxaban once daily, beginning after surgery, or 40 mg of enoxaparin subcutaneously once daily, beginning the evening before surgery, plus a placebo tablet or injection. The primary efficacy outcome was the composite of deep-vein thrombosis (either symptomatic or detected by bilateral venography if the patient was asymptomatic), nonfatal pulmonary embolism, or death from any

NEJM2008

88. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. 18579812 2008 06 26 2008 07 01 2015 11 19 1533-4406 358 26 2008 Jun 26 The New England journal of medicine N. Engl. J. Med. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. 2776-86 10.1056/NEJMoa076016 We investigated the efficacy of rivaroxaban, an orally active direct factor Xa inhibitor, in preventing venous thrombosis after total knee arthroplasty. In this randomized (...) , double-blind trial, 2531 patients who were to undergo total knee arthroplasty received either oral rivaroxaban, 10 mg once daily, beginning 6 to 8 hours after surgery, or subcutaneous enoxaparin, 40 mg once daily, beginning 12 hours before surgery. The primary efficacy outcome was the composite of any deep-vein thrombosis, nonfatal pulmonary embolism, or death from any cause within 13 to 17 days after surgery. Secondary efficacy outcomes included major venous thromboembolism (i.e., proximal

NEJM2008

89. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial.

Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. 18582928 2008 07 08 2008 07 17 2015 11 19 1474-547X 372 9632 2008 Jul 05 Lancet (London, England) Lancet Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. 31-9 10.1016/S0140-6736(08)60880-6 (...) The risk of venous thromboembolism is high after total hip arthroplasty and could persist after hospital discharge. Our aim was to compare the use of rivaroxaban for extended thromboprophylaxis with short-term thromboprophylaxis with enoxaparin. 2509 patients scheduled to undergo elective total hip arthroplasty were randomly assigned, stratified according to centre, with a computer-generated randomisation code, to receive oral rivaroxaban 10 mg once daily for 31-39 days (with placebo injection for 10

Lancet2008

90. Rivaroxaban (Bay 59-7939) for the prevention of venous thromboembolism (VTE) after major orthopaedic surgery: horizon scanning technology briefing

Rivaroxaban (Bay 59-7939) for the prevention of venous thromboembolism (VTE) after major orthopaedic surgery: horizon scanning technology briefing Rivaroxaban (Bay 59-7939) for the prevention of venous thromboembolism (VTE) after major orthopaedic surgery: horizon scanning technology briefing Rivaroxaban (Bay 59-7939) for the prevention of venous thromboembolism (VTE) after major orthopaedic surgery: horizon scanning technology briefing National Horizon Scanning Centre Record Status (...) This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Horizon Scanning Centre. Rivaroxaban (Bay 59-7939) for the prevention of venous thromboembolism (VTE) after major orthopaedic surgery: horizon scanning technology briefing. Birmingham: National Horizon Scanning Centre (NHSC). 2007 Authors' objectives This study examines the use of Rivaroxaban (Bay 59-7939

Health Technology Assessment (HTA) Database.2007